-Tetramisole.gif)
In vitro: L-tetramisole (250 and 500 mg/mL) suppresses IFN synthesis in the cells from BALB/c and NZB mice. L-tetramisole (125 mg/mL) inhibits the IFN production only partially and this effect is observed when the IFN production is high. L-tetramisole affects the production of the physiological IFN, but not the production of IFN induced by Newcastle disease virus (NDV) in the peritoneal cells of mice or in L929 cells. In vivo: Tetramisole leads to the mean faecal egg count rose from 3 weeks after treatment and remain continuously higher than those Closantel or Albendazole treated group up to 12 weeks after treatment. Tetramisole reduces neuronal response amplitude in a dose-dependent manner in mouse cortex. Tetramisole also decreases axonal conduction velocity in mouse cortex. Tetramisole significantly increases the stereotyped behavior (grooming, sniffing, biting and licking and head bobbing) of the mice when compared to the control group. Tetramisole significantly increases stereotyped behavior of the mice on days 3, 5 and 8 in comparison with respective control values. Tetramisole treatments (0.5 and 1mg/kg) also significantly decreases the time needed to complete the negative geotaxis task and reduces landing foot splay.
| Molecular Weight | 240.75 |
| Formula | C11H12N2S.HCl |
| CAS Number | 16595-80-5 |
| Solubility (25°C) | 48 mg/mL in water |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Products |
|---|
| M3554 (anti-GD2 ADC)
M3554 is a novel anti-GD2 ADC designed based on humanized ch14.18 anti-GD2 antibody. M3554 has anti-tumor activity. |
| OGT2115
OGT2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT2115 has anti-angiogenic properties (IC50 = 1 μM). |
| DiosMetin 7-O-β-D-Glucuronide
DiosMetin 7-O-β-D-Glucuronide is an antioxidant constituent in the fruits of Luffa cylindrical. |
| Bendazac L-Lysine
Bendazac L-Lysine is an aldose reductase (AR) inhibitor, which can be used to inhibit the activity of AR in the eye to prevent cataracts. |
| Ro5-3335
Ro5-3335 acts as an inhibitor of core binding factor (CBF) leukemia. Ro5-3335 is a RUNX1-CBFβ interaction inhibitor that represses RUNX1/CBFB-dependent transactivation. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
